About bsbh

This author has not yet filled in any details.
So far bsbh has created 248 blog entries.

Adrien Lemoine

Adrien Lemoine VP Business Development & Operations, Orchard Therapeutics Adrien brings to Orchard Therapeutics more than 15 years of experience growing pharma and biotech businesses via in- and out-licensing, M&A and portfolio development. Prior to joining Orchard, Adrien was Executive Director, Corporate Strategy and Development at AstraZeneca where he was leading M&A [...]

Adrien Lemoine2017-10-27T07:34:51+02:00

Deborah Morrison

Deborah Morrison Senior Scientific Adviser, NICE Deborah leads on several strategic initiatives within the scientific advice team. She holds an Honours Degree in Pharmacy and a Clinical Diploma in Clinical Pharmacy. Previously, Deborah was responsible for developing a series of combined clinical and commissioning roles within Cambridgeshire Primary Care Trust and NHS Cambridgeshire [...]

Deborah Morrison2017-08-09T09:14:59+02:00

Barbara Freischem

Barbara Freischem Executive Director, European Biopharmaceutical Enterprises (EBE) Barbara Freischem is Executive Director of the European Biopharmaceutical Enterprises (EBE), since July 2015. EBE is a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing biopharmaceutical companies of all sizes. Barbara has worked at national, European and international level. Starting [...]

Barbara Freischem2017-08-09T09:15:00+02:00

Magda Papadaki

Magda Papadaki Head of Product and Process Innovation, Association of the British Pharmaceutical Industry (ABPI) Dr Magda Papadaki, is Head of Product and Process Innovation for ABPI. She is responsible for UK’s pharma strategy in innovative products and ATMPs, new Synthetic Biology R&D tools and novel platforms for their production and regulatory/clinical [...]

Magda Papadaki2017-10-27T07:30:22+02:00

Qasim Rafiq

Qasim Rafiq Senior Lecturer (Assistant Professor) Bioprocessing of Regenerative, Cellular and Gene Therapies, UCL I am currently a Lecturer (Assistant Professor) in Bioprocess Engineering at Aston University with a specific research focus on the manufacture, translation and commercialisation of cell, gene and tissue-based therapies. In my first 12 months as a Lecturer, I [...]

Qasim Rafiq2017-08-09T09:15:00+02:00

James McBlane

James McBlane CAT Member, Preclinical Assessor, UK Medicines and Healthcare Products Regulatory Agency (MHRA) After degrees in pharmacology at Dundee and Aston universities, Dr McBlane worked for Wellcome and then at the UK Medicines Control Agency before moving to the Japanese biopharmaceutical company, Chugai, for 10 years, latterly specialising in preclinical development.  He [...]

James McBlane2017-08-09T09:15:00+02:00

Andrew Plump

Andrew Plump, M.D., Ph.D. Chief Medical and Scientific Officer, Takeda In 2015, Andrew Plump, M.D., Ph.D., joined Takeda as Chief Medical and Scientific Officer (CMSO). Dr. Plump also serves as a member of Takeda’s Executive Team and of the company’s Board of Directors. In his position, he leads Takeda’s global Research & Development [...]

Andrew Plump2017-08-09T09:15:00+02:00

Keith Thompson

Keith Thompson CEO, Cell and Gene Therapy Catapult Keith has established a team of over 120 cell and gene therapy experts in state-of-the-art laboratories in London and is now building a large-scale manufacturing centre. Keith joined the Cell and Gene Therapy Catapult from the Scottish Blood Transfusion Service where he was National Director, [...]

Keith Thompson2017-08-09T09:15:00+02:00

Eduardo Bravo

Eduardo Bravo Founder and Chief Executive Officer, TiGenix President, EBE Prior to joining TiGenix in 2005, Eduardo held several senior management and commercial positions at Sanofi-Aventis and SmithKline Beecham, lastly as Vice President for Latin America for Sanofi-Aventis. He holds a degree in Business Administration and an MBA from INSEAD. Eduardo is President [...]

Eduardo Bravo2017-08-09T09:15:00+02:00

Seigo Izumo

Seigo Izumo, MD Senior Vice President, Global Head of Regenerative Medicine Unit & Head of Scientific Affairs Japan, Takeda Pharmaceutical Company Ltd. Dr. Seigo Izumo is Senior Vice President, Global Head of Regenerative Medicine Unit and Head of Scientific Affairs Japan at Takeda Pharmaceutical Company. He is responsible for Takeda’s strategic initiative [...]

Seigo Izumo2017-11-02T08:22:50+02:00
Go to Top